celecoxib has been researched along with Cancer of Skin in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 9.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| " Dacarbazine (DTIC) is one of the most commonly used drugs in the treatment of metastatic melanoma." | 7.83 | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. ( Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016) |
| " This study was designed to investigate the effects of the mTOR antagonist rapamycin and the COX 2 inhibitor celecoxib on cell growth and apoptosis in malignant melanoma." | 7.74 | Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. ( Becker, B; Bundscherer, A; Hafner, C; Landthaler, M; Maisch, T; Vogt, T, 2008) |
| "Melanoma is a highly drug resistant cancer." | 5.46 | Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. ( Gowda, R; Robertson, GP; Sharma, A, 2017) |
| "Celecoxib, which was approved by Health Canada for familial adenomatous polyposis coli, was offered to 27 patients with surgically incurable recurrent melanoma, 87 percent of whom had stage M1c disease." | 5.33 | Clinical activity of celecoxib in metastatic malignant melanoma. ( Wilson, KS, 2006) |
| " We then assessed the effects of celecoxib on the development of BCCs in a 3-year, double-blinded, randomized clinical trial in 60 (PTCH1(+/-)) patients with the basal cell nevus syndrome." | 5.14 | Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. ( Aszterbaum, M; Athar, M; Barsanti, F; Bickers, DR; Cappola, C; Epstein, EH; Estevez, N; Hebert, J; Hwang, J; Khaimskiy, Y; Kim, A; Kohn, MA; Kopelovich, L; Lu, Y; McCulloch, CE; So, PL; Tang, JY; Tang, X, 2010) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 5.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| " Dacarbazine (DTIC) is one of the most commonly used drugs in the treatment of metastatic melanoma." | 3.83 | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine. ( Averineni, RK; Guan, X; Sadhu, SS; Seefeldt, T; Wang, S; Yang, Y, 2016) |
| " This study was designed to investigate the effects of the mTOR antagonist rapamycin and the COX 2 inhibitor celecoxib on cell growth and apoptosis in malignant melanoma." | 3.74 | Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. ( Becker, B; Bundscherer, A; Hafner, C; Landthaler, M; Maisch, T; Vogt, T, 2008) |
| "Paclitaxel has antiangiogenic properties, but the mechanisms for the enhanced sensitivity of endothelial cells (ECs) to this drug are not established." | 2.71 | Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. ( Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG, 2005) |
| "Melanoma is a model tumor in immuno-oncology." | 2.66 | COX-2 as a potential biomarker and therapeutic target in melanoma. ( Bâldea, I; Gabriela Filip, A; Hopârtean, A; Kacso, T; Kutasi, E; Lupu, M; Stretea, R; Tudor, DV, 2020) |
| "Deoxynivalenol is a trichothecene mycotoxin which naturally contaminates small grain, cereals intended for human and animal consumption." | 1.56 | N-acetyl-cysteine in combination with celecoxib inhibits Deoxynivalenol induced skin tumor initiation via induction of autophagic pathways in swiss mice. ( Asthana, S; Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mishra, S; Rath, SK; Sharma, D; Srivastava, S; Wahajuddin, M, 2020) |
| "Cotreatment with celecoxib and 5-FU partially blocked AKT phosphorylation, although no significant changes in total AKT protein levels were detected." | 1.46 | Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production. ( Ahn, SH; Choi, JJ; Kim, YH; Kwon, SK; Lee, DY; Oh, SM; Park, SW; Shin, ES; Sung, MW, 2017) |
| "Melanoma is a highly drug resistant cancer." | 1.46 | Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. ( Gowda, R; Robertson, GP; Sharma, A, 2017) |
| "Human cutaneous melanoma is an aggressive and chemotherapy-resistant type of cancer." | 1.42 | AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. ( Adinolfi, B; Breschi, MC; Carpi, S; Costa, B; Da Pozzo, E; Fogli, S; Martini, C; Nieri, P; Pellegrino, M; Podestà, A; Romanini, A, 2015) |
| "Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15-30% of patients with BRAF(V600E) metastatic melanoma treated with BRAF inhibitors (BRAFi)." | 1.40 | COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. ( Atefi, M; Avramis, E; Cass, A; Cochran, AJ; Comin-Anduix, B; Escuin-Ordinas, H; Fu, Y; Graeber, TG; Herschman, HR; Huang, RR; Lo, RS; Marais, R; Ng, C; Ribas, A; Yashar, S, 2014) |
| "Treatment with celecoxib had effects on inflammation response and reduced cancer metastasis." | 1.39 | Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis. ( Bi, Y; Han, M; Jia, J; Jiang, M; Liu, Q; Xu, J; Xu, X, 2013) |
| " Neither association was observed when stratified by NSAID type (aspirin and other NSAIDs), nor did dose-response patterns emerge by frequency of use (average days per month)." | 1.38 | Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study. ( Alexander, BH; Cahoon, EK; Doody, MM; Freedman, DM; Linet, MS; Rajaraman, P, 2012) |
| "Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide." | 1.35 | Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. ( Jalili, A; Karlhofer, FM; Pieczkowski, F; Pinc, A; Stingl, G; Wagner, SN, 2008) |
| "Skin cancer is the most common cancer, and often occurs in the head and neck region." | 1.35 | Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009) |
| "Celecoxib, which was approved by Health Canada for familial adenomatous polyposis coli, was offered to 27 patients with surgically incurable recurrent melanoma, 87 percent of whom had stage M1c disease." | 1.33 | Clinical activity of celecoxib in metastatic malignant melanoma. ( Wilson, KS, 2006) |
| "Over a million nonmelanoma skin cancer cases will be reported in the United States this year alone." | 1.32 | Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. ( Koki, AT; Oberyszyn, TM; Rubal, PA; Wilgus, TA; Zweifel, BS, 2003) |
| "The ratios of squamous cell carcinomas to papillomas and of sebaceous gland adenomas to papillomas plus squamous cell carcinomas were increased markedly in transgenic mice treated with DMBA alone compared with DMBA/phorbol 12-myristate 13-acetate-treated transgenic and wild-type mice." | 1.31 | Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. ( Berger, I; Furstenberger, G; Marks, F; Muller-Decker, K; Neufang, G; Neumann, M, 2002) |
| "Celecoxib is an effective and safe chemopreventive agent in UV carcinogenesis." | 1.31 | Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. ( Black, HS; Gerguis, J; Guevara, A; Lewis, AT; Orengo, IF; Phillips, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 19 (40.43) | 29.6817 |
| 2010's | 22 (46.81) | 24.3611 |
| 2020's | 3 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Tudor, DV | 1 |
| Bâldea, I | 1 |
| Lupu, M | 1 |
| Kacso, T | 1 |
| Kutasi, E | 1 |
| Hopârtean, A | 1 |
| Stretea, R | 1 |
| Gabriela Filip, A | 1 |
| Mishra, S | 1 |
| Divakar, A | 1 |
| Srivastava, S | 1 |
| Dewangan, J | 1 |
| Sharma, D | 1 |
| Asthana, S | 1 |
| Chaturvedi, S | 1 |
| Wahajuddin, M | 1 |
| Kumar, S | 1 |
| Rath, SK | 1 |
| Singh, S | 1 |
| Quiñones, OG | 1 |
| Pierre, MBR | 1 |
| Laquer, V | 1 |
| Dellinger, RW | 1 |
| Mannering, I | 1 |
| Garcia, AG | 1 |
| Abraham, V | 1 |
| Pavlis, J | 1 |
| Liu-Smith, F | 1 |
| De Feraudy, S | 1 |
| Meyskens, FL | 2 |
| Kelly, KM | 1 |
| Reimer, A | 1 |
| Lu, S | 1 |
| He, Y | 1 |
| Bruckner-Tuderman, L | 1 |
| Technau-Hafsi, K | 1 |
| Meiss, F | 1 |
| Has, C | 1 |
| von Bubnoff, D | 1 |
| Escuin-Ordinas, H | 1 |
| Atefi, M | 1 |
| Fu, Y | 1 |
| Cass, A | 1 |
| Ng, C | 1 |
| Huang, RR | 1 |
| Yashar, S | 1 |
| Comin-Anduix, B | 1 |
| Avramis, E | 1 |
| Cochran, AJ | 1 |
| Marais, R | 1 |
| Lo, RS | 1 |
| Graeber, TG | 1 |
| Herschman, HR | 1 |
| Ribas, A | 1 |
| Carpi, S | 1 |
| Fogli, S | 1 |
| Romanini, A | 1 |
| Pellegrino, M | 1 |
| Adinolfi, B | 1 |
| Podestà, A | 1 |
| Costa, B | 1 |
| Da Pozzo, E | 1 |
| Martini, C | 1 |
| Breschi, MC | 1 |
| Nieri, P | 1 |
| Sadhu, SS | 1 |
| Wang, S | 1 |
| Averineni, RK | 1 |
| Seefeldt, T | 1 |
| Yang, Y | 1 |
| Guan, X | 1 |
| Sung, MW | 1 |
| Lee, DY | 1 |
| Park, SW | 1 |
| Oh, SM | 1 |
| Choi, JJ | 1 |
| Shin, ES | 1 |
| Kwon, SK | 1 |
| Ahn, SH | 1 |
| Kim, YH | 1 |
| Gowda, R | 1 |
| Sharma, A | 1 |
| Robertson, GP | 1 |
| Ueno, M | 1 |
| Namiki, T | 1 |
| Inui, K | 1 |
| Hanafusa, T | 1 |
| Miura, K | 1 |
| Yokozeki, H | 1 |
| Jalili, A | 1 |
| Pinc, A | 1 |
| Pieczkowski, F | 1 |
| Karlhofer, FM | 1 |
| Stingl, G | 1 |
| Wagner, SN | 1 |
| Becker, MR | 1 |
| Gaiser, T | 1 |
| Fegn, L | 1 |
| Wang, Z | 1 |
| Wulff, BC | 1 |
| Thomas-Ahner, JM | 2 |
| Schick, JS | 1 |
| Oberyszyn, TM | 5 |
| Tang, JY | 1 |
| Aszterbaum, M | 1 |
| Athar, M | 1 |
| Barsanti, F | 1 |
| Cappola, C | 1 |
| Estevez, N | 1 |
| Hebert, J | 1 |
| Hwang, J | 1 |
| Khaimskiy, Y | 1 |
| Kim, A | 1 |
| Lu, Y | 1 |
| So, PL | 1 |
| Tang, X | 1 |
| Kohn, MA | 1 |
| McCulloch, CE | 1 |
| Kopelovich, L | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 1 |
| Bhatt, RS | 1 |
| Merchan, J | 1 |
| Parker, R | 1 |
| Wu, HK | 1 |
| Zhang, L | 1 |
| Seery, V | 1 |
| Heymach, JV | 1 |
| Atkins, MB | 1 |
| McDermott, D | 1 |
| Sukhatme, VP | 2 |
| Kopp, KL | 1 |
| Dabelsteen, S | 1 |
| Krejsgaard, T | 1 |
| Eriksen, KW | 1 |
| Geisler, C | 1 |
| Becker, JC | 1 |
| Wasik, M | 1 |
| Ødum, N | 1 |
| Woetmann, A | 1 |
| McLaren, CE | 1 |
| Elmets, CA | 1 |
| Viner, JL | 1 |
| Pentland, AP | 3 |
| Cantrell, W | 1 |
| Lin, HY | 1 |
| Bailey, H | 1 |
| Kang, S | 1 |
| Linden, KG | 1 |
| Heffernan, M | 1 |
| Duvic, M | 1 |
| Richmond, E | 1 |
| Elewski, BE | 1 |
| Umar, A | 1 |
| Bell, W | 1 |
| Gordon, GB | 2 |
| Cahoon, EK | 1 |
| Rajaraman, P | 1 |
| Alexander, BH | 1 |
| Doody, MM | 1 |
| Linet, MS | 1 |
| Freedman, DM | 1 |
| Ellebaek, E | 1 |
| Engell-Noerregaard, L | 1 |
| Iversen, TZ | 1 |
| Froesig, TM | 1 |
| Munir, S | 1 |
| Hadrup, SR | 1 |
| Andersen, MH | 1 |
| Svane, IM | 1 |
| Rodust, PM | 1 |
| Fecker, LF | 1 |
| Stockfleth, E | 1 |
| Eberle, J | 1 |
| Han, M | 1 |
| Xu, J | 1 |
| Bi, Y | 1 |
| Jiang, M | 1 |
| Xu, X | 1 |
| Liu, Q | 1 |
| Jia, J | 1 |
| Konger, RL | 1 |
| Xu, Z | 1 |
| Sahu, RP | 1 |
| Rashid, BM | 1 |
| Mehta, SR | 1 |
| Mohamed, DR | 1 |
| DaSilva-Arnold, SC | 1 |
| Bradish, JR | 1 |
| Warren, SJ | 1 |
| Kim, YL | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Muller-Decker, K | 1 |
| Neufang, G | 1 |
| Berger, I | 1 |
| Neumann, M | 1 |
| Marks, F | 1 |
| Furstenberger, G | 1 |
| Fischer, SM | 4 |
| Conti, CJ | 2 |
| Viner, J | 1 |
| Aldaz, CM | 1 |
| Lubet, RA | 2 |
| Wilgus, TA | 4 |
| Koki, AT | 2 |
| Zweifel, BS | 2 |
| Rubal, PA | 2 |
| Kusewitt, DF | 2 |
| Akunda, JK | 1 |
| Lao, HC | 1 |
| Lee, CA | 1 |
| Sessoms, AR | 1 |
| Slade, RM | 1 |
| Langenbach, R | 1 |
| Won, YK | 1 |
| Ong, CN | 1 |
| Shi, X | 1 |
| Shen, HM | 1 |
| Breza, TS | 1 |
| Tober, KL | 2 |
| Merchan, JR | 1 |
| Jayaram, DR | 1 |
| Supko, JG | 1 |
| He, X | 1 |
| Bubley, GJ | 1 |
| Maruyama, T | 1 |
| Gogas, H | 1 |
| Polyzos, A | 1 |
| Stavrinidis, I | 1 |
| Frangia, K | 1 |
| Tsoutsos, D | 1 |
| Panagiotou, P | 1 |
| Markopoulos, C | 1 |
| Papadopoulos, O | 1 |
| Pectasides, D | 1 |
| Mantzourani, M | 1 |
| Middleton, M | 1 |
| Vaiopoulos, G | 1 |
| Fountzilas, G | 1 |
| Wilson, KS | 1 |
| Riedel, SB | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Bundscherer, A | 1 |
| Hafner, C | 1 |
| Maisch, T | 1 |
| Becker, B | 1 |
| Landthaler, M | 1 |
| Vogt, T | 1 |
| Ziegler, J | 1 |
| Lo, HH | 1 |
| Seibert, K | 1 |
| Kelloff, G | 1 |
| Schoggins, JW | 1 |
| Scott, GA | 1 |
| Khan, KN | 1 |
| Han, R | 1 |
| Bol, DK | 1 |
| Rowley, RB | 1 |
| Ho, CP | 1 |
| Pilz, B | 1 |
| Dell, J | 1 |
| Swerdel, M | 1 |
| Kiguchi, K | 1 |
| Muga, S | 1 |
| Klein, R | 1 |
| Orengo, IF | 1 |
| Gerguis, J | 1 |
| Phillips, R | 1 |
| Guevara, A | 1 |
| Lewis, AT | 1 |
| Black, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses[NCT00027976] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2001-12-31 | Withdrawn | ||
| Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Malignant Melanoma. Phase I/II Study[NCT00197912] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
2 reviews available for celecoxib and Cancer of Skin
| Article | Year |
|---|---|
COX-2 as a potential biomarker and therapeutic target in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Celecoxib; Clinical Tria | 2020 |
Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygena | 2019 |
7 trials available for celecoxib and Cancer of Skin
| Article | Year |
|---|---|
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; | 2010 |
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administrati | 2010 |
Celecoxib may decrease some skin cancers.
Topics: Animals; Carcinoma, Basal Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Mice; Pyrazoles; Ski | 2010 |
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous | 2010 |
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C | 2012 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2005 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
38 other studies available for celecoxib and Cancer of Skin
| Article | Year |
|---|---|
N-acetyl-cysteine in combination with celecoxib inhibits Deoxynivalenol induced skin tumor initiation via induction of autophagic pathways in swiss mice.
Topics: Acetylcysteine; Animals; Autophagy; Celecoxib; Mice; Skin Neoplasms; Trichothecenes | 2020 |
Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Celecoxib; Cell Line, Tumor; Cell | 2018 |
12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Biopsy; Carcinoma, Squamous Cell; Celecoxib; Chemopreven | 2018 |
Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; C | 2020 |
COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; | 2014 |
AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channels; Celecoxib; Cell Line, Tumor; Cell Survival; Cycl | 2015 |
In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dacarbazine; Disease Models, An | 2016 |
Celecoxib enhances the inhibitory effect of 5-FU on human squamous cell carcinoma proliferation by ROS production.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Celeco | 2017 |
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2017 |
Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antineoplast | 2017 |
Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2008 |
Impressive regression of visceral and cerebral melanoma metastases under combination treatment including dacarbacine, radiotherapy and celecoxib.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Combined Modality Therapy | 2009 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy | 2009 |
Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.
Topics: Animals; Blotting, Western; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Cyclosporine; Dinoprost | 2010 |
COX-2 is a novel target in therapy of mycosis fungoides.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Humans; Ki-67 Antigen; Mice; Myco | 2010 |
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2010 |
Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States Radiologic Technologists study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Basal Cell; Cele | 2012 |
Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; C | 2012 |
Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis.
Topics: Animals; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytokines; Female; Inflammation; | 2013 |
Spatiotemporal assessments of dermal hyperemia enable accurate prediction of experimental cutaneous carcinogenesis as well as chemopreventive activity.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents; Carcinogens; Celecoxib; Cell Tr | 2013 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib | 2002 |
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Disease Progr | 2003 |
Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.
Topics: Administration, Topical; Animals; Celecoxib; Cell Division; Cyclooxygenase 2; Dinoprostone; Disease | 2003 |
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; | 2003 |
Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or -2 induces mouse keratinocyte differentiation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Differentiation; Cells, Cultured; Cycloox | 2004 |
Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Blotting, West | 2004 |
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Celecoxib; Cell Division; Cycloox | 2004 |
Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development.
Topics: Animals; Celecoxib; Cinnamates; Cyclooxygenase Inhibitors; Dermatitis; Female; Keratinocytes; Mice; | 2006 |
Clinical activity of celecoxib in metastatic malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; Melano | 2006 |
Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice.
Topics: Acetates; Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; C | 2008 |
Early trials probe COX-2 inhibitors' cancer-fighting potential.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1999 |
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Celecoxib; Cell Division; Cyclooxygen | 1999 |
Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 1999 |
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Alopecia; Animals; Carcinogens; Celecoxib; Cyclooxygenase 2; Cyclo | 2002 |
Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model.
Topics: Animals; Biopsy, Needle; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; | 2002 |
Cyclooxygenase inhibitors for skin cancer prevention: are they beneficial enough?
Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Melanoma; Prognosis | 2002 |